Long-term outcomes of ruxolitinib (RUX) therapy in patients (pts) with myelofibrosis (MF): 5-year update from COMFORT-I.

被引：0

作者：

Gupta, Vikas

Verstovsek, Srdan

Mesa, Ruben A.

Gotlib, Jason R.

DiPersio, John F.

Catalano, John V.

Deininger, Michael W. N.

Miller, Carole Brennan

Silver, Richard T.

Talpaz, Moshe

Winton, Elliott F.

Harvey, Jimmie Huling

Arcasoy, Murat.

Hexner, Elizabeth O.

Lyons, Roger M.

Paquette, Ronald

Raza, Azra

Kornacki, Deanna

Sun, Kang

Kantarjian, Hagop M.

机构：

[1] Univ Toronto, Princess Margaret Hosp, Toronto, ON, Canada

[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[3] Mayo Clin, Scottsdale, AZ USA

[4] Stanford Univ, Sch Med, Stanford Canc Ctr, Stanford, CA 94305 USA

[5] Washington Univ, Sch Med, St Louis, MO 63110 USA

[6] Frankston Hosp, Frankston, Australia

[7] Dept Clin Haematol, Frankston, Australia

[8] Oregon Hlth & Sci Univ, Portland, OR 97201 USA

[9] St Agnes Canc Inst, Baltimore, MD USA

[10] Weill Cornell Med Ctr, New York, NY USA

[11] Univ Michigan, Ann Arbor, MI 48109 USA

[12] Emory Univ, Sch Med, Atlanta, GA 30322 USA

[13] Birmingham Hematol Oncol Associates, Birmingham, AL USA

[14] Duke Univ, Hlth Syst, Durham, NC USA

[15] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[16] Canc Care Ctr South Texas, US Oncol, San Antonio, TX USA

[17] Univ Calif Los Angeles, Ronald Reagan UCLA Med Ctr, Los Angeles, CA USA

[18] Columbia Univ, Med Ctr, New York, NY USA

[19] Incyte Corp, Wilmington, DE USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期

关键词：

D O I：

10.1200/JCO.2016.34.15_suppl.7012

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

7012

引用

页数：4

共 50 条

[1] LONG-TERM OUTCOMES OF RUXOLITINIB (RUX) THERAPY IN PATIENTS (PTS) WITH MYELOFIBROSIS (MF): 5-YEAR FINAL EFFICACY AND SAFETY ANALYSIS FROM COMFORT-I
Verstovsek, S.
Mesa, R. A.
Gotlib, J. R.
Gupta, V.
DiPersio, J. F.
Catalano, J. V.
Deininger, M. W.
Miller, C. B.
Silver, R. T.
Talpaz, M.
Winton, E. F.
Harvey, J. H., Jr.
Arcasoy, M. O.
Hexner, E. O.
Lyons, R. M.
Paquette, R.
Raza, A.
Jones, M.
Kornacki, D.
Sun, K.
Kantarjian, H.
HAEMATOLOGICA, 2016, 101 : 162 - 163
[2] Long-Term Outcomes Of Ruxolitinib Therapy In Patients With Myelofibrosis: 3-Year Update From COMFORT-I
Verstovsek, Srdan
Mesa, Ruben A.
Gotlib, Jason
Levy, Richard S.
Gupta, Vikas
Dipersio, John F.
Catalano, John V.
Deininger, Michael W.
Miller, Carole B.
Silver, Richard T.
Talpaz, Moshe
Winton, Elliott F.
Harvey, Jimmie H., Jr.
Arcasoy, Murat O.
Hexner, Elizabeth
Lyons, Roger M.
Paquette, Ronald
Raza, Azra
Vaddi, Kris
Sun, William
Peng, Wei
Sandor, Victor A.
Kantarjian, Hagop M.
BLOOD, 2013, 122 (21)
[3] RUXOLITINIB (RUX) IN COMBINATION WITH 5-AZACYTIDINE (AZA) AS THERAPY FOR PATIENTS (PTS) WITH MYELOFIBROSIS (MF)
Daver, N.
Cortes, J.
Zhou, L.
Pemmaraju, N.
Jabbour, E.
Borthakur, G.
Estrov, Z.
Garcia-Manero, G.
Kantarjian, H.
Verstovsek, S.
HAEMATOLOGICA, 2015, 100 : 161 - 162
[4] Ruxolitinib (RUX) in Combination with 5-Azacytidine (AZA) As Therapy for Patients (pts) with Myelofibrosis (MF)
Daver, Naval
Cortes, Jorge E.
Pemmaraju, Naveen
Jabbour, Elias J.
Bose, Prithviraj
Zhou, Lingsha
Pierce, Sherry
Van derbur, Stephanie
Borthakur, Gautam
Estrov, Zeev
Garcia-Manero, Guillermo
Kantarjian, Hagop M.
Verstovsek, Srdan
BLOOD, 2016, 128 (22)
[5] Effects of Long-Term Ruxolitinib (RUX) on Bone Marrow (BM) Morphology in Patients with Myelofibrosis (MF) Enrolled in the COMFORT-I Study
Kvasnicka, Hans Michael
Thiele, Juergen
Bueso-Ramos, Carlos E.
Sun, William
Naim, Ahmad
Svaraman, Smitha
Gao, Jessy
Gotlib, Jason R.
Gupta, Vikas
Dao, Kim-Hien
Talpaz, Moshe
Winton, Elliott F.
Harvey, Jimmie H., Jr.
Verstovsek, Srdan
BLOOD, 2016, 128 (22)
[6] Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial
Verstovsek, Srdan
Mesa, Ruben A.
Gotlib, Jason
Gupta, Vikas
DiPersio, John F.
Catalano, John V.
Deininger, Michael W. N.
Miller, Carole B.
Silver, Richard T.
Talpaz, Moshe
Winton, Elliott F.
Harvey, Jimmie H., Jr.
Arcasoy, Murat O.
Hexner, Elizabeth O.
Lyons, Roger M.
Paquette, Ronald
Raza, Azra
Jones, Mark
Kornacki, Deanna
Sun, Kang
Kantarjian, Hagop
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2017, 10 : 1 - 14
[7] Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial
Srdan Verstovsek
Ruben A. Mesa
Jason Gotlib
Vikas Gupta
John F. DiPersio
John V. Catalano
Michael W. N. Deininger
Carole B. Miller
Richard T. Silver
Moshe Talpaz
Elliott F. Winton
Jimmie H. Harvey
Murat O. Arcasoy
Elizabeth O. Hexner
Roger M. Lyons
Ronald Paquette
Azra Raza
Mark Jones
Deanna Kornacki
Kang Sun
Hagop Kantarjian
Journal of Hematology & Oncology, 10
[8] LONG-TERM OUTCOMES FROM A PHASE 3 STUDY COMPARING RUXOLITINIB WITH BEST AVAILABLE THERAPY ( BAT) FOR THE TREATMENT OF MYELOFIBROSIS (MF): A 3-YEAR UPDATE OF COMFORT-II
Vannucchi, A.
Cervantes, F.
Niederwieser, D.
Sirulnik, A.
Stalbovskaya, V.
McQuitty, M.
Levy, R.
Passamonti, F.
Barbui, T.
Gisslinger, H.
Knoops, L.
Harrison, C.
Barosi, G.
Kiladjian, J.
HAEMATOLOGICA, 2013, 98 : 456 - 457
[9] Clinical Outcomes with Ruxolitinib (RUX) in Patients with Myelofibrosis (MF) Stratified By Transfusion Status: A Pooled Analysis of the COMFORT-I and -II Trials
Gupta, Vikas
Verstovsek, Srdan
Paquette, Ronald
Gotlib, Jason R.
Vannucchi, Alessandro M.
Kiladjian, Jean-Jacques
Cervantes, Francisco
Sun, William
Gao, Jessy
Langmuir, Peter
Gopalakrishna, Prashanth
Harrison, Claire N.
BLOOD, 2016, 128 (22)
[10] Ruxolitinib (RUX) retreatment in patients (Pts) with myelofibrosis (MF): Real-world evidence on pt characteristics and outcomes.
Pemmaraju, Naveen
Yu, Jingbo
Parasuraman, Shreekant
Paranagama, Dilan
Kish, Jonathan
Visaria, Jay
Singhal, Mukul
Verstovsek, Srdan
Gerds, Aaron Thomas
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)

← 1 2 3 4 5 →